Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics–Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging

Background Cardiac magnetic resonance imaging (CMR) is the gold standard for the quantification of global and regional myocardial function and can detect subclinical myocardial dysfunction in anthracycline-induced cardiomyopathy. The aim of this study was to ascertain reliable echocardiographic parameters that can be used for the early identification of cancer therapeutics–related cardiac dysfunction, compared with CMR. Methods Fifty-seven pediatric cancer survivors, 10 to 42 years of age, with cumulative anthracycline doses ≥ 200 mg/m 2 , were studied with transthoracic echocardiography and CMR 2.4 to 26.9 years after chemotherapy. Results Three-dimensional echocardiography had the highest sensitivity in identifying subjects with CMR-derived ejection fractions   29 mL/m 2 were more likely to have CMR-derived ejection fractions  Conclusions Three-dimensional echocardiographic ejection fraction   29 mL/m 2 , three-dimensional speckle-tracking echocardiographic peak global longitudinal strain magnitude